FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563941750> ?p ?o ?g. }

• W2563941750 abstract "Abstract The proteasome inhibitor bortezomib enhances the effect of the selective estrogen receptor (ER) downregulator (SERD) fulvestrant by causing accumulation of cytoplasmic ER aggregates in preclinical models. The purpose of this trial was to determine whether bortezomib enhanced the effectiveness of fulvestrant. One hundred eighteen postmenopausal women with ER-positive metastatic breast cancer resistant to aromatase inhibitors (AIs) were randomized to fulvestrant alone (Arm A—500 mg intramuscular (i.m.) day −14, 1, 15 in cycle 1, and day 1 of additional cycles) or in combination with bortezomib (Arm B—1.6 mg/m 2 intravenous (i.v.) on days 1, 8, 15 of each cycle). The study was powered to show an improvement in median progression-free survival (PFS) from 5.4 to 9.0 months and compare PFS rates at 6 and 12 months ( α =0.10, β =0.10). Patients with progression on fulvestrant could cross over to the combination (arm C). Although there was no difference in median PFS (2.7 months in both arms), the hazard ratio for PFS in Arm B versus Arm A (referent) was 0.73 (95% confidence interval (CI)=0.49, 1.09, P =0.06, 1-sided log-rank test, significant at the prespecified 1-sided 0.10 α level). At 12 months, the PFS proportion in Arm A and Arm B was 13.6% and 28.1% ( P =0.03, 1-sided χ 2 -test; 95% CI for difference (14.5%)=−0.06, 29.1%). Of 27 patients on arm A who crossed over to the combination (arm C), 5 (18%) were progression-free for at least 24 weeks. Bortezomib likely enhances the effectiveness of fulvestrant in AI-resistant, ER-positive metastatic breast cancer by reducing acquired resistance, supporting additional evaluation of proteasome inhibitors in combination with SERDs." @default.
• W2563941750 created "2017-01-06" @default.
• W2563941750 creator A5002450423 @default.
• W2563941750 creator A5003104262 @default.
• W2563941750 creator A5004522625 @default.
• W2563941750 creator A5009199118 @default.
• W2563941750 creator A5015548619 @default.
• W2563941750 creator A5021570988 @default.
• W2563941750 creator A5022891785 @default.
• W2563941750 creator A5024592292 @default.
• W2563941750 creator A5027148722 @default.
• W2563941750 creator A5027165899 @default.
• W2563941750 creator A5028063287 @default.
• W2563941750 creator A5033039574 @default.
• W2563941750 creator A5051244727 @default.
• W2563941750 creator A5051867478 @default.
• W2563941750 creator A5052323489 @default.
• W2563941750 creator A5055781858 @default.
• W2563941750 creator A5067587535 @default.
• W2563941750 creator A5070602177 @default.
• W2563941750 creator A5080151636 @default.
• W2563941750 creator A5084530547 @default.
• W2563941750 creator A5085623893 @default.
• W2563941750 creator A5085875361 @default.
• W2563941750 creator A5088253295 @default.
• W2563941750 creator A5090359583 @default.
• W2563941750 creator A5091772334 @default.
• W2563941750 date "2016-12-14" @default.
• W2563941750 modified "2023-10-01" @default.
• W2563941750 title "Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial" @default.
• W2563941750 cites W1523693806 @default.
• W2563941750 cites W1656816575 @default.
• W2563941750 cites W1912976527 @default.
• W2563941750 cites W1981472752 @default.
• W2563941750 cites W2002483881 @default.
• W2563941750 cites W2007624356 @default.
• W2563941750 cites W2016663561 @default.
• W2563941750 cites W2019607817 @default.
• W2563941750 cites W2030587663 @default.
• W2563941750 cites W2041694372 @default.
• W2563941750 cites W2054857153 @default.
• W2563941750 cites W2062510022 @default.
• W2563941750 cites W2069364002 @default.
• W2563941750 cites W2070790769 @default.
• W2563941750 cites W2084941037 @default.
• W2563941750 cites W2098407557 @default.
• W2563941750 cites W2100085165 @default.
• W2563941750 cites W2102685625 @default.
• W2563941750 cites W2118305948 @default.
• W2563941750 cites W2129958055 @default.
• W2563941750 cites W2131890640 @default.
• W2563941750 cites W2133667885 @default.
• W2563941750 cites W2139726760 @default.
• W2563941750 cites W2142334766 @default.
• W2563941750 cites W2150887511 @default.
• W2563941750 cites W2154533342 @default.
• W2563941750 cites W2161551022 @default.
• W2563941750 cites W2167188058 @default.
• W2563941750 cites W2296942186 @default.
• W2563941750 cites W2404884142 @default.
• W2563941750 cites W4238222546 @default.
• W2563941750 doi "https://doi.org/10.1038/npjbcancer.2016.37" @default.
• W2563941750 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5515340" @default.
• W2563941750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28721390" @default.
• W2563941750 hasPublicationYear "2016" @default.
• W2563941750 type Work @default.
• W2563941750 sameAs 2563941750 @default.
• W2563941750 citedByCount "21" @default.
• W2563941750 countsByYear W25639417502015 @default.
• W2563941750 countsByYear W25639417502017 @default.
• W2563941750 countsByYear W25639417502018 @default.
• W2563941750 countsByYear W25639417502019 @default.
• W2563941750 countsByYear W25639417502020 @default.
• W2563941750 countsByYear W25639417502021 @default.
• W2563941750 countsByYear W25639417502022 @default.
• W2563941750 countsByYear W25639417502023 @default.
• W2563941750 crossrefType "journal-article" @default.
• W2563941750 hasAuthorship W2563941750A5002450423 @default.
• W2563941750 hasAuthorship W2563941750A5003104262 @default.
• W2563941750 hasAuthorship W2563941750A5004522625 @default.
• W2563941750 hasAuthorship W2563941750A5009199118 @default.
• W2563941750 hasAuthorship W2563941750A5015548619 @default.
• W2563941750 hasAuthorship W2563941750A5021570988 @default.
• W2563941750 hasAuthorship W2563941750A5022891785 @default.
• W2563941750 hasAuthorship W2563941750A5024592292 @default.
• W2563941750 hasAuthorship W2563941750A5027148722 @default.
• W2563941750 hasAuthorship W2563941750A5027165899 @default.
• W2563941750 hasAuthorship W2563941750A5028063287 @default.
• W2563941750 hasAuthorship W2563941750A5033039574 @default.
• W2563941750 hasAuthorship W2563941750A5051244727 @default.
• W2563941750 hasAuthorship W2563941750A5051867478 @default.
• W2563941750 hasAuthorship W2563941750A5052323489 @default.
• W2563941750 hasAuthorship W2563941750A5055781858 @default.
• W2563941750 hasAuthorship W2563941750A5067587535 @default.
• W2563941750 hasAuthorship W2563941750A5070602177 @default.
• W2563941750 hasAuthorship W2563941750A5080151636 @default.
• W2563941750 hasAuthorship W2563941750A5084530547 @default.
• W2563941750 hasAuthorship W2563941750A5085623893 @default.
• W2563941750 hasAuthorship W2563941750A5085875361 @default.
• W2563941750 hasAuthorship W2563941750A5088253295 @default.

• next